XML 43 R30.htm IDEA: XBRL DOCUMENT v3.21.2
1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Apr. 02, 2019
Noncontrolling interests   $ (136,914) $ (132,124)  
Increase (decrease) in noncontrolling interest   (4,790)    
Cash equivalents   0 0  
Cash balances over insured amount   9,712,000    
Asset impairment charges   $ 0 $ 0  
Shares considered antidilutive   2,836,062 2,072,492  
Amortization of deferred financing costs   $ 0 $ 0  
Revenue recognized   659,104 650,187  
Research and development expenses   2,072,000 927,000  
Restricted cash   46,726 0  
Revenues   659,104 650,187  
Lease liabilities       $ 228,694
Right-of-use lease assets   40,363 136,426 $ 228,694
National Institute of Health [Member]        
Revenue recognized   659,104 650,187  
National Institute of Health [Member] | Melanoma Cancer Contract Phase 2 [Member]        
Revenue recognized   436,427    
Revenue recorded, previously accrued $ 117,849 318,578    
Deferred revenue   114,849    
National Institute of Health [Member] | Breast Cancer Grant [Member]        
Revenue recognized   $ 188,444 $ 34,233  
ESI [Member]        
Equity ownership percentage   80.00% 80.00%  
Noncontrolling interests   $ (136,914) $ (132,124)